# Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015

> **NCT03782467** · PHASE1 · COMPLETED · sponsor: **Alligator Bioscience AB** · enrollment: 33 (actual)

## Conditions studied

- Solid Tumor
- Neoplasms

## Interventions

- **BIOLOGICAL:** ATOR-1015

## Key facts

- **NCT ID:** NCT03782467
- **Lead sponsor:** Alligator Bioscience AB
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-30
- **Primary completion:** 2021-03-03
- **Final completion:** 2021-03-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03782467

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03782467, "Phase 1 Study in Patients With Advanced and/or Refractory Solid Malignancies to Evaluate the Safety of ATOR-1015". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03782467. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*